UNSPSC 51451807: Albendazole sulfoxide

This classification denotes an antihelminthic agent with the molecular formula C12H15N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J39B52TV34, chemically known as methyl (5-(propylsulfinyl)-1h-benzo(d)imidazol-2-yl)carbamate, but more generally known as albendazole sulfoxide, which bears US NIH Compound Identifier 83969. European Medicines Agency schedules albendazole sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05295MIG.

Most nations, for tariff purposes, schedule albendazole sulfoxide under HS 29339990. SMILES: CCC[S+](C1CCC2C(C1)NC([NH]2)NC(=O)OC)[O-].

UNSPSC 51451807 Albendazole sulfoxide is a Commodity code for a specific pharmaceutical active ingredient, yet the recent state and local opportunities posted under this code show little alignment with its nominal scope. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets, neither of which is albendazole sulfoxide; Seminole County, Florida posted an IFB for Naloxone and drug deactivation systems, also unrelated to the code's stated product. The mismatch suggests either miscategorization at the posting stage or that this code does not reflect current state and local procurement activity for albendazole sulfoxide specifically.

The geographic activity visible in these records spans Illinois and Florida, though neither opportunity actually targets the commodity named in the code. The Illinois contract, awarded August 28, 2026, was an IFB resulting in a $2,999,999.11 award over 12 months plus two renewal options; the Seminole County IFB, posted June 30, 2026 with a July 26, 2023 response deadline (an apparent data inconsistency), sought quarterly deliveries of naloxone and deactivation systems. Without recent opportunities genuinely soliciting albendazole sulfoxide or products within its therapeutic class, the code shows no actionable procurement signal for vendors in that product family at the state and local level.